Cellular Basis of Steroid Glaucoma
Principal Investigator
Jorge Alvarado, MD
University of California, San Francisco
San Francisco, CA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 1995 - March 31, 1997
Grant ID
G1995402
Summary
Glaucoma is a blinding disease affecting millions of Americans. This disease causes blindness because the eye pressure becomes elevated and this pressure can destroy the optic nerve without which one cannot see. Treatment of the eye with steroid eye drops can result in an increase in pressure inside the eye, and in some individuals steroids can actually cause glaucoma, and loss of vision. The purpose of the research outlined in this grant proposal is to discover the reasons that steroid treatment can cause increased pressure, and to use this knowledge to develop potential means to prevent and treat this type of glaucoma. It is even likely that such new treatment approaches may help us develop new medications for other types of glaucoma. There are two layers of cells through which the clear fluid in the eye, or aqueous humor, must pass as it drains from the eye to return to the circulation. Normally, the aqueous can flow through small spaces which lie between the cells in these layers. Through study of human cells kept alive and growing in a healthy state, we are seeking to understand how the passage of fluid through them can be regulated. Early results from these experiments indicate that with steroid treatment, the channels between cells are narrowed, and the flow is clearly reduced.
Related Grants
National Glaucoma Research
Improving Glaucoma Care with Agentic AI
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Mark Christopher, PhD
Current Organization
University of California, San Diego
Improving Glaucoma Care with Agentic AI
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Mark Christopher, PhD
Current Organization
University of California, San Diego
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System